AVDL - フラメル・テクノロジ―ズ (Avadel Pharmaceuticals plc) フラメル・テクノロジ―ズ

 AVDLのチャート


 AVDLの企業情報

symbol AVDL
会社名 Avadel Pharmaceuticals PLC (フラメル・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms including Micropump LiquiTime Trigger Lock and Medusa. The Company offers its products in various categories including hospital including Bloxiverz Vazculep and Akovaz and pediatrics including Karbinal ER Cefaclor for Oral Suspension AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media lower respiratory infections pharyngitis and tonsillitis urinary tract infections and skin and skin structure infections caused by susceptible organisms.   フラメル・テクノロジ―ズはフランスのバイオ医薬品メ―カ―。ポリマ―ベ―スの薬剤送達技術を開発。マイクロポンプ技術は、放出制御、味覚マスキング及び生物学的利用強化の応用で小分子薬の経口投与を実現。メデュ―サ技術は、治療用たんぱく質、ペプチド、その他の大小分子薬の注入後の制御放出を行う。グラクソ・スミスクラインなどとの共同開発を行う。   
本社所在地 Block 10-1 Blanchardstown Corporate Park Ballycoolin Dublin 15 IRL
代表者氏名 Michael S. Anderson マイケル・S・アンダーソン
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +353 1-485-1200
設立年月日 33086
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 180人
url www.avadel.com
nasdaq_url https://www.nasdaq.com/symbol/avdl
adr_tso 41900230
EBITDA EBITDA(百万ドル) -8.02700
終値(lastsale) 4.46
時価総額(marketcap) 186875025.8
時価総額 時価総額(百万ドル) 171.32290
売上高 売上高(百万ドル) 136.95000
企業価値(EV) 企業価値(EV)(百万ドル) 175.41290
当期純利益 当期純利益(百万ドル) -5.75300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avadel Pharmaceuticals PLC (ADR) revenues decreased 37% to $62.5M. Net loss totaled $15.7M vs. income of $54.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest Expense increase from $526K to $4.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.33 to -$0.41.

 AVDLのテクニカル分析


 AVDLのニュース

   Avadel's Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy Patients  2021/04/19 11:05:31 Benzinga
Avadel Pharmaceuticals Plc (NASDAQ: AVDL ) has announced the presentation of secondary endpoint data from the Phase 3 REST-ON trial evaluating FT218 once-nightly formulation of sodium oxybate (ON-SXB) for excessive daytime sleepiness and cataplexy in adults with narcolepsy. Narcolepsy is a chronic sleep disorder characterized by daytime drowsiness and sudden attacks of sleep. People with narcolepsy … Full story available on Benzinga.com
   Avadel Pharmaceuticals : Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy | MarketScreener  2021/03/01 13:01:57 MarketScreener
DUBLIN, Ireland, March 01, 2021 -- Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application for… | March 1, 2021
   Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA  2020/12/16 13:00:00 GlobeNewswire
DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application…
   Avadel Pharmaceuticals : Added to NASDAQ Biotechnology Index | MarketScreener  2020/12/15 13:03:18 MarketScreener
DUBLIN, Ireland, Dec. 15, 2020 -- Avadel Pharmaceuticals plc , a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive… | December 15, 2020
   Avadel Pharmaceuticals (NASDAQ:AVDL) Lowered to “Strong Sell” at BidaskClub  2020/10/25 08:06:43 Dakota Financial News
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports. Several other research firms also recently weighed in on AVDL. Oppenheimer initiated coverage on Avadel Pharmaceuticals in a report on Thursday, July 30th. They issued a “buy” […]
   Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA  2020/12/16 13:00:00 GlobeNewswire
DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application…
   Avadel Pharmaceuticals : Added to NASDAQ Biotechnology Index | MarketScreener  2020/12/15 13:03:18 MarketScreener
DUBLIN, Ireland, Dec. 15, 2020 -- Avadel Pharmaceuticals plc , a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive… | December 15, 2020
   Avadel Pharmaceuticals (NASDAQ:AVDL) Lowered to “Strong Sell” at BidaskClub  2020/10/25 08:06:43 Dakota Financial News
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports. Several other research firms also recently weighed in on AVDL. Oppenheimer initiated coverage on Avadel Pharmaceuticals in a report on Thursday, July 30th. They issued a “buy” […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Rating Lowered by BidaskClub  2020/10/25 04:06:42 The Lincolnian
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Friday, BidAskClub reports. Several other research analysts have also issued reports on the company. Ci Capital reaffirmed a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Downgraded to Strong Sell at BidaskClub  2020/10/24 08:52:41 Stock Observer
BidaskClub cut shares of Avadel Pharmaceuticals (NASDAQ:AVDL) from a sell rating to a strong sell rating in a report issued on Friday morning, BidAskClub reports. AVDL has been the topic of several other reports. Ci Capital reiterated a buy rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a research report […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Lowered to “Strong Sell” at BidaskClub  2020/10/25 08:06:43 Dakota Financial News
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports. Several other research firms also recently weighed in on AVDL. Oppenheimer initiated coverage on Avadel Pharmaceuticals in a report on Thursday, July 30th. They issued a “buy” […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Rating Lowered by BidaskClub  2020/10/25 04:06:42 The Lincolnian
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Friday, BidAskClub reports. Several other research analysts have also issued reports on the company. Ci Capital reaffirmed a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Downgraded to Strong Sell at BidaskClub  2020/10/24 08:52:41 Stock Observer
BidaskClub cut shares of Avadel Pharmaceuticals (NASDAQ:AVDL) from a sell rating to a strong sell rating in a report issued on Friday morning, BidAskClub reports. AVDL has been the topic of several other reports. Ci Capital reiterated a buy rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a research report […]
   Avadel Pharmaceuticals plc to Post FY2022 Earnings of ($0.18) Per Share, SVB Leerink Forecasts (NASDAQ:AVDL)  2020/10/24 04:54:41 The Lincolnian
Avadel Pharmaceuticals plc (NASDAQ:AVDL) – SVB Leerink decreased their FY2022 earnings estimates for Avadel Pharmaceuticals in a report issued on Tuesday, October 20th. SVB Leerink analyst A. Fadia now anticipates that the company will post earnings per share of ($0.18) for the year, down from their prior forecast of ($0.13). SVB Leerink currently has a […]
   FY2022 EPS Estimates for Avadel Pharmaceuticals plc (NASDAQ:AVDL) Reduced by Analyst  2020/10/23 01:56:47 Daily Political
Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities research analysts at SVB Leerink lowered their FY2022 earnings per share estimates for shares of Avadel Pharmaceuticals in a report released on Tuesday, October 20th. SVB Leerink analyst A. Fadia now forecasts that the company will earn ($0.18) per share for the year, down from their previous estimate of […]

 関連キーワード  (医薬品 米国株 フラメル・テクノロジ―ズ AVDL Avadel Pharmaceuticals plc)

 twitter  (公式ツイッターやCEOツイッターなど)